Versanis Bio is a clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The company’s lead asset, bimagrumab, is being advanced in a Phase 2b study as a novel treatment for obesity to help adults achieve and maintain both substantial fat loss and a healthy body composition, with additional indications to follow.
| Headquarters | New York, NY |
| Website | www.versanisbio.com |
| Pipeline Status | Phase 2b |
| @VersanisBio | |
| Versanis Bio |